Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal, Marcelo E ; Edvinsson, Lars LU ; Rapoport, Alan M ; Lipton, Richard B ; Spierings, Egilius L H ; Diener, Hans-Christoph ; Burstein, Rami ; Loupe, Pippa S ; Ma, Yuju and Yang, Ronghua , et al. (2015) In Lancet Neurology 14(11). p.1091-1100
Abstract
Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Lancet Neurology
volume
14
issue
11
pages
1091 - 1100
publisher
Lancet Publishing Group
external identifiers
  • pmid:26432181
  • wos:000362975200013
  • scopus:84944039741
ISSN
1474-4465
DOI
10.1016/S1474-4422(15)00245-8
language
English
LU publication?
yes
id
977e84f2-dd6a-4d84-9469-097a0e561521 (old id 8159005)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26432181?dopt=Abstract
date added to LUP
2016-04-01 10:26:24
date last changed
2025-10-14 10:30:02
@article{977e84f2-dd6a-4d84-9469-097a0e561521,
  abstract     = {{Benefits of calcitonin-gene related peptide (CGRP) inhibition have not been established in chronic migraine. Here we assess the safety, tolerability, and efficacy of two doses of TEV-48125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.}},
  author       = {{Bigal, Marcelo E and Edvinsson, Lars and Rapoport, Alan M and Lipton, Richard B and Spierings, Egilius L H and Diener, Hans-Christoph and Burstein, Rami and Loupe, Pippa S and Ma, Yuju and Yang, Ronghua and Silberstein, Stephen D}},
  issn         = {{1474-4465}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{1091--1100}},
  publisher    = {{Lancet Publishing Group}},
  series       = {{Lancet Neurology}},
  title        = {{Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.}},
  url          = {{http://dx.doi.org/10.1016/S1474-4422(15)00245-8}},
  doi          = {{10.1016/S1474-4422(15)00245-8}},
  volume       = {{14}},
  year         = {{2015}},
}